On Monday, the health and wellness platform Hims & Hers Health Inc HIMS shares traded higher after the company announced the addition of GLP-1 injections to its weight loss portfolio.
The company now offers access to GLP-1 injections and weight management oral medication kits.
Access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Novo Nordisk A/S’s NVO Ozempic and Wegovy without navigating the shortages and costs currently limiting access to the branded medications.
Through a partnership with a US manufacturer of generic and 503B compounded injectable medications, Hims & Hers can help millions of obesity patients.
Hims & Hers expects its weight loss program to generate more than $100 million in revenue by the end of 2025.
GLP-1 injections are fulfilled and shipped from Hims & Hers’ affiliated pharmacies.
Once consistent supply is available through the pharmacies’ wholesaler, Hims & Hers plans to make branded options available to customers, expanding the offering beyond the current oral medication kits and compounded GLP-1 injectable medications.
Weight loss medications are priced at $79/month for oral medication kits and $199/month for compounded GLP-1 injections.
Pricing includes unlimited medical consultations with a licensed provider.
Oral medication kits and compounded GLP-1 injections are not available in all states.
Price Action: HIMS shares are up 34.9% at $19.65 at last check Monday.
Photo by Vidmir Rais via Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
